Literature DB >> 20545012

Urinary neutrophil gelatinase-associated lipocalin: A potential biomarker for predicting rapid progression of drug-induced chronic tubulointerstitial nephritis.

Yu Wu1, Tao Su, Li Yang, Sai-Nan Zhu, Xiao-Mei Li.   

Abstract

INTRODUCTION: The role of urinary biomarkers of kidney injury in the prediction of adverse clinical outcomes in drug-induced chronic tubulointerstitial nephritis (D-CTIN) has not been well described.
METHODS: A total of 36 patients with D-CTIN were enrolled in the study. The baseline urinary excretion of neutrophil gelatinase-associated lipocalin (NGAL), alpha1-microglobin (alpha1-MG), albumin (mAlb) and total protein were measured, and estimated glomerular filtration rate change rates within a period of 6 to 33 (mean: 24 months) follow-up months were recorded.
RESULTS: Areas under the receiver-operator characteristic curve of urinary NGAL, alpha1-MG, mAlb and total protein for predicting deterioration of estimated glomerular filtration rate were 0.707, 0.631, 0.685 and 0.678, respectively. The cutoff points that maximized the combined sensitivity and specificity for NGAL, alpha1-MG, mAlb and total protein were 37.71 ng/mL, 33.20 microg/mL, 6.91 mg/L and 60.00 mg/L, respectively. At these thresholds, the sensitivity and specificity was 64.7% and 78.9% for NGAL, 66.7% and 50.0% for alpha1-MG, 80.0% and 50.0% for mAlb and 70.6% and 63.2% for total protein, respectively. The median renal survival time (years) of patients with urinary NGAL level exceeding 37.705 ng/mL was shorter than that of patients with urinary NGAL level below 37.705 ng/mL (1.59 +/- 0.79 versus 2.09 +/- 0.63, P = 0.040, chi(2) = 4.218).
CONCLUSIONS: Increase of baseline urinary NGAL was better than alpha1-MG, mAlb and total protein in predicting renal function deterioration in patients with D-CTIN. This noninvasive approach has potential to serve as a practical tool in D-CTIN prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20545012     DOI: 10.1097/maj.0b013e3181dd0cb1

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

Review 1.  Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury.

Authors:  Sandra L Kane-Gill; Pamela L Smithburger; Kianoush Kashani; John A Kellum; Erin Frazee
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

2.  Neutrophil gelatinase-associated lipocalin as a biomarker of disease progression in patients with chronic kidney disease.

Authors:  M L Patel; R Sachan; A Verma; R Kamal; K K Gupta
Journal:  Indian J Nephrol       Date:  2016 Mar-Apr

3.  Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease.

Authors:  Kathleen D Liu; Wei Yang; Amanda H Anderson; Harold I Feldman; Sevag Demirjian; Takayuki Hamano; Jiang He; James Lash; Eva Lustigova; Sylvia E Rosas; Michael S Simonson; Kaixiang Tao; Chi-yuan Hsu
Journal:  Kidney Int       Date:  2013-01-23       Impact factor: 10.612

4.  Human Kidney Tubule-Specific Gene Expression Based Dissection of Chronic Kidney Disease Traits.

Authors:  Pazit Beckerman; Chengxiang Qiu; Jihwan Park; Nora Ledo; Yi-An Ko; Ae-Seo Deok Park; Sang-Youb Han; Peter Choi; Matthew Palmer; Katalin Susztak
Journal:  EBioMedicine       Date:  2017-09-18       Impact factor: 8.143

Review 5.  Evaluation value of neutrophil gelatinase-associated lipocalin for the renal dysfunction of patients with chronic kidney disease: A meta-analysis.

Authors:  Lulu Guo; Yaya Zhao; Zhenzhu Yong; Weihong Zhao
Journal:  Aging Med (Milton)       Date:  2018-09-26

6.  Evaluation of serum neutrophil gelatinase-associated lipocalin in older patients with chronic kidney disease.

Authors:  Lulu Guo; Bei Zhu; Haichuan Yuan; Weihong Zhao
Journal:  Aging Med (Milton)       Date:  2020-03-27

7.  Early Markers of Tubulointerstitial Fibrosis in Children With Idiopathic Nephrotic Syndrome: Preliminary Report.

Authors:  Beata Bieniaś; Małgorzata Zajączkowska; Halina Borzęcka; Przemysław Sikora; Anna Wieczorkiewicz-Płaza; Barbara Wilczyńska
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.